{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T04:09:41Z","timestamp":1793246981181,"version":"4.5.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.ejim.2023.01.029","type":"journal-article","created":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T02:19:57Z","timestamp":1675736397000},"page":"62-70","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Trends in prevalence and all-cause mortality of metabolic dysfunction-associated fatty liver disease among adults in the past three decades: Results from the NHANES study"],"prefix":"10.1016","volume":"110","author":[{"given":"Zhi-Qin","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Xia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing-Kun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao-Ming","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Liang","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-Bin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Kai","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Wei","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4629-7682","authenticated-orcid":false,"given":"Chang-Zhen","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Jin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.ejim.2023.01.029_bib0001","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.ejim.2023.01.029_bib0002","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41575-020-00381-6","article-title":"Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention","volume":"18","author":"Huang","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.ejim.2023.01.029_bib0003","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1136\/gutjnl-2019-318813","article-title":"Epidemiology of chronic liver diseases in the USA in the past three decades","volume":"69","author":"Younossi","year":"2020","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.ejim.2023.01.029_bib0004","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1053\/j.gastro.2018.08.024","article-title":"Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease","volume":"155","author":"Kanwal","year":"2018","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.ejim.2023.01.029_bib0005","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/s41575-021-00448-y","article-title":"The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments","volume":"18","author":"Targher","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.ejim.2023.01.029_bib0006","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.ejim.2023.01.029_bib0007","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S2468-1253(22)00062-0","article-title":"Global multi-stakeholder endorsement of the MAFLD definition","volume":"7","author":"Mendez-Sanchez","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.ejim.2023.01.029_bib0008","doi-asserted-by":"crossref","DOI":"10.1177\/20420188221139101","article-title":"MAFLD: what 2 years of the redefinition of fatty liver disease has taught us","volume":"13","author":"Grabherr","year":"2022","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.ejim.2023.01.029_bib0009","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/hep.32131","article-title":"Metabolic dysfunction-associated fatty liver disease improves detection of high liver stiffness: the Rotterdam Study","volume":"75","author":"van Kleef","year":"2022","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.ejim.2023.01.029_bib0010","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1111\/hepr.13685","article-title":"MAFLD better predicts the progression of atherosclerotic cardiovascular risk than NAFLD: generalized estimating equation approach","volume":"51","author":"Tsutsumi","year":"2021","journal-title":"Hepatol Res"},{"issue":"1","key":"10.1016\/j.ejim.2023.01.029_bib0011","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S2468-1253(20)30294-6","article-title":"Redefining fatty liver disease: an international patient perspective","volume":"6","author":"Shiha","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.ejim.2023.01.029_bib0012","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1111\/liv.14548","article-title":"Comparison of MAFLD and NAFLD diagnostic criteria in real world","volume":"40","author":"Lin","year":"2020","journal-title":"Liver Int"},{"issue":"4","key":"10.1016\/j.ejim.2023.01.029_bib0013","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.jhep.2021.06.013","article-title":"Are the different MAFLD subtypes based on the inclusion criteria correlated with all-cause mortality?","volume":"75","author":"Chen","year":"2021","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.ejim.2023.01.029_bib0014","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1002\/hep.32499","article-title":"Are there outcome differences between NAFLD and metabolic-associated fatty liver disease?","volume":"76","author":"Younossi","year":"2022","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.ejim.2023.01.029_bib0015","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1210\/clinem\/dgab339","article-title":"Metabolic dysfunction-associated fatty liver disease (MAFLD)-Rather a bystander than a driver of mortality","volume":"106","author":"Semmler","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.ejim.2023.01.029_bib0016","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.jhep.2021.07.035","article-title":"Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States","volume":"75","author":"Kim","year":"2021","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.ejim.2023.01.029_bib0017","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.jhep.2022.01.015","article-title":"A simpler definition of MAFLD better predicts long-term all-cause mortality in American adults","volume":"77","author":"Xie","year":"2022","journal-title":"J Hepatol"},{"issue":"10","key":"10.1016\/j.ejim.2023.01.029_bib0018","first-page":"2172","article-title":"Differential clinical characteristics and mortality outcomes in persons with NAFLD and\/or MAFLD.Clin Gastroenterol Hepatol","volume":"19","author":"Nguyen","year":"2021"},{"issue":"4","key":"10.1016\/j.ejim.2023.01.029_bib0019","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s12072-022-10362-3","article-title":"A new risk stratification strategy for fatty liver disease by incorporating MAFLD and fibrosis score in a large US population","volume":"16","author":"Zhang","year":"2022","journal-title":"Hepatol Int"},{"issue":"3","key":"10.1016\/j.ejim.2023.01.029_bib0020","doi-asserted-by":"crossref","first-page":"433","DOI":"10.5009\/gnl210167","article-title":"Metabolic dysfunction-associated fatty liver disease predicts long-term mortality and cardiovascular disease","volume":"16","author":"Moon","year":"2022","journal-title":"Gut Liver"},{"issue":"184","key":"10.1016\/j.ejim.2023.01.029_bib0021","first-page":"1","article-title":"National health and nutrition examination survey, 2015-2018: sample design and estimation procedures","volume":"2","author":"Chen","year":"2020","journal-title":"Vital Health Stat"},{"issue":"1","key":"10.1016\/j.ejim.2023.01.029_bib0022","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/apt.13012","article-title":"Fatty liver indices in the multiethnic United States National Health and Nutrition examination survey","volume":"41","author":"Ruhl","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl 1","key":"10.1016\/j.ejim.2023.01.029_bib0023","first-page":"S14","article-title":"American diabetes A. 2. Classification and diagnosis of diabetes: standards of medical care in Diabetes-2020","volume":"43","year":"2020","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.ejim.2023.01.029_bib0024","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1007\/s12072-022-10407-7","article-title":"Long-term cardiovascular outcomes differ across metabolic dysfunction-associated fatty liver disease subtypes among middle-aged population","volume":"16","author":"Lee","year":"2022","journal-title":"Hepatol Int"},{"issue":"20","key":"10.1016\/j.ejim.2023.01.029_bib0025","first-page":"1","article-title":"Age adjustment using the 2000 projected U.S. population","author":"Klein","year":"2001","journal-title":"Healthy People 2010 Stat Notes"},{"key":"10.1016\/j.ejim.2023.01.029_bib0026","doi-asserted-by":"crossref","DOI":"10.4093\/dmj.2021.0327","article-title":"Metabolic dysfunction-associated fatty liver disease and mortality: a population-based cohort study","author":"Kim","year":"2023","journal-title":"Diabetes Metab J"},{"issue":"1","key":"10.1016\/j.ejim.2023.01.029_bib0027","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1186\/s12933-022-01697-0","article-title":"Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention","volume":"21","author":"Zhou","year":"2022","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"10.1016\/j.ejim.2023.01.029_bib0028","doi-asserted-by":"crossref","first-page":"250","DOI":"10.5604\/01.3001.0010.8644","article-title":"More evidence for the genetic susceptibility of Mexican population to nonalcoholic fatty liver disease through PNPLA3","volume":"17","author":"Chinchilla-Lopez","year":"2018","journal-title":"Ann Hepatol"},{"issue":"1","key":"10.1016\/j.ejim.2023.01.029_bib0029","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12916-022-02716-3","article-title":"Lean or diabetic subtypes predict increased all-cause and disease-specific mortality in metabolic-associated fatty liver disease","volume":"21","author":"Chung","year":"2023","journal-title":"BMC Med"},{"issue":"23","key":"10.1016\/j.ejim.2023.01.029_bib0030","doi-asserted-by":"crossref","DOI":"10.3390\/nu14234969","article-title":"The diagnostic and prognostic value of the triglyceride-glucose index in metabolic dysfunction-associated fatty liver disease (MAFLD): a systematic review and Meta-analysis","volume":"14","author":"Wang","year":"2022","journal-title":"Nutrients"},{"key":"10.1016\/j.ejim.2023.01.029_bib0031","article-title":"The lipid accumulation product is a powerful tool to diagnose metabolic dysfunction-associated fatty liver disease in the United States adults","volume":"13","author":"Li","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"8","key":"10.1016\/j.ejim.2023.01.029_bib0032","doi-asserted-by":"crossref","first-page":"e3295","DOI":"10.1210\/clinem\/dgac283","article-title":"Remnant cholesterol predicts long-term mortality of patients with metabolic dysfunction-associated fatty liver disease","volume":"107","author":"Huang","year":"2022","journal-title":"J Clin Endocrinol Metab"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620523000341?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620523000341?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T09:37:48Z","timestamp":1760607468000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620523000341"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":32,"alternative-id":["S0953620523000341"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2023.01.029","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trends in prevalence and all-cause mortality of metabolic dysfunction-associated fatty liver disease among adults in the past three decades: Results from the NHANES study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2023.01.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}